AI Summary & Key Takeaways
AI InsightT-wavepeak to end (Tp-e), QT ranges, P-wave dispersion (Pd), and R-R range were measured.Then, the Schizophrenia Positive and Negative Syndrome Scale (PANSS) and the CalgaryDepression Scale for Schizophrenia (CDSS) were applied to the schizophrenia group.Results: The PANSS positive symptom subscale was calculated as 10.41 (SD = 2.27), thenegative symptom subscale was calculated as 14.44 (SD = 5.42), and the overall functionalitylevel was calculated as 27.04 (SD = 5.43).
📌 3 Key Takeaways
Abstract
Objective: The purpose of this study was to examine electrocardiographic ventricular arrhythmiapredictors in patients with schizophrenia by comparing with healthy controls.Methods: The study included 100 patients with schizophrenia and 100 healthy controls.Electrocardiography (ECG) was performed on all participants in resting position. T-wavepeak to end (Tp-e), QT ranges, P-wave dispersion (Pd), and R-R range were measured.Then, the Schizophrenia Positive and Negative Syndrome Scale (PANSS) and the CalgaryDepression Scale for Schizophrenia (CDSS) were applied to the schizophrenia group.Results: The PANSS positive symptom subscale was calculated as 10.41 (SD = 2.27), thenegative symptom subscale was calculated as 14.44 (SD = 5.42), and the overall functionalitylevel was calculated as 27.04 (SD = 5.43). The mean CDSS score was determined to be3.74 (SD = 2.15). No differences were detected in the heart rate measurements of the patientand control groups in ECG results (P = .427). The minimum QT interval and minimumTp-e wave times were found to be low in the patient group (P < .001 for both intervals).Corrected QTc dispersion, Pd, Tp-e dispersion, and QT dispersion were found to be higherin the patient group than in healthy controls (P < .001 for all intervals).Discussion: Based on our results, it is possible to speculate that patients with schizophreniaare at a risk of developing cardiac arrhythmia and cardiac dysfunction if they do notreceive treatment. For this reason, clinicians should pay attention to cardiac transmissionproblems when organizing the treatment of patients. Further studies should be conductedto determine cardiac problems in patients with schizophrenia.